Biophytis Announces Phase 2 Clinical Study in Obesity Treatment with BIO101

Biophytis SA, a biotechnology firm focused on developing therapeutics for age-related diseases, has initiated the OBA phase 2 clinical study targeting obesity with its drug candidate BIO101 (20-hydroxyecdysone), in combination with GLP-1 receptor agonists. This move comes after promising preclinical results showing BIO101's potential benefits in muscle and fat tissue metabolism. The study, expected to commence in mid-2024, aims to address the muscle loss associated with obesity treatment methods, especially those involving GLP-1 receptor agonists which lead to significant muscle loss during weight reduction.

The obesity medication market in the US is poised for growth, with projections showing a potential $100 billion value by 2030. BIO101's preclinical successes in enhancing muscle strength and reducing fat mass present a promising solution to the muscle wasting dilemma faced by obesity patients undergoing treatment with GLP-1 RAs. The anticipated OBA Phase 2 clinical study will delve deeper into these effects, with results expected by 2025.

Stanislas Veillet, CEO of Biophytis, expressed optimism about BIO101's ability to preserve muscle function in obesity patients treated with GLP-1 RAs. If regulatory approvals are secured, BIO101 could address a significant medical challenge and solidify Biophytis's position in a rapidly expanding market. Veillet highlights the company's commitment to accelerating the clinical development of BIO101, poised to make a substantial impact on treating obesity-related muscle deterioration.